AlfaKinetic
by Anervea
LandscapeMonitorCompareProfileAsk
principle

Nothing is shown without a source. When the data can’t answer, the product says so.

LB Pharmaceuticals
tenant
drug

OPUS YOUNG

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
BEHAVIORAL
Pre-approval / investigational in the US
Developed by Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
BEHAVIORAL

Indications

Investigational (via trials)
SchizophreniaSchizotypal DisorderAcute and Transient Psychotic Disorder, UnspecifiedDepression SevereSubstance Induced PsychosesSchizotypal Personality DisorderMental DisordersSchizophreniaNon-Organic PsychosisDelusional DisorderPsychoses, Substance-InducedPsychotic DisordersSchizoaffective DisorderSchizophrenia, Paranoid

Trials

1
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
NCT04916626—Active Not Recruiting

KOLs & investigators

1
Anne K Pagsberg, PhD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
company
trial
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
NA
trial
indication
Schizophrenia
indication
Schizotypal Disorder
indication
Acute and Transient Psychotic Disorder, Unspecified
indication
Depression Severe
indication
KOL
Anne K Pagsberg, PhD
KOL score —
person